Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription


2 Am J Clin Pathol
1 BJU Int
2 BMC Urol
1 Br J Cancer
1 Cancer Imaging
1 Cancer Lett
1 Discov Oncol
1 Endocrinology
1 Eur J Radiol
3 Eur Urol
1 Hum Pathol
1 J Natl Cancer Inst
2 Prostate
1 Radiologia (Engl Ed)
2 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Pathol

  1. MARLETTA S, Eccher A, Martelli FM, Santonicco N, et al
    Artificial intelligence-based algorithms for the diagnosis of prostate cancer: A systematic review.
    Am J Clin Pathol. 2024 Feb 21:aqad182. doi: 10.1093.
    PubMed         Abstract available

  2. BERGHOLTZ SE, Kurnot SR, Elahi E, DeJonckheere M, et al
    A longitudinal mixed-methods study of pathology explanation clinics in patients with newly diagnosed localized prostate cancer.
    Am J Clin Pathol. 2024 Feb 22:aqae008. doi: 10.1093.
    PubMed         Abstract available

    BJU Int

  3. HONORE A, Moen CA, Juliebo-Jones P, Reisaeter LAR, et al
    Transitioning from transrectal to transperineal prostate biopsy using a freehand cognitive approach.
    BJU Int. 2024;133:324-331.
    PubMed         Abstract available

    BMC Urol

  4. GOUDARZI Z, Lotfi F, Najafpour Z, Hafezi A, et al
    Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran.
    BMC Urol. 2024;24:45.
    PubMed         Abstract available

  5. FENG X, Chen X, Peng P, Zhou H, et al
    Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
    BMC Urol. 2024;24:40.
    PubMed         Abstract available

    Br J Cancer

  6. LIU Q, Zhang Y, Vaselkiv JB, Mucci LA, et al
    A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02593.
    PubMed         Abstract available

    Cancer Imaging

  7. ROSAR F, Burgard C, Larsen E, Khreish F, et al
    [(89)Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [(68)Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
    Cancer Imaging. 2024;24:27.
    PubMed         Abstract available

    Cancer Lett

  8. CHEN H, Dong K, Ding J, Xia J, et al
    CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
    Cancer Lett. 2024 Feb 14:216725. doi: 10.1016/j.canlet.2024.216725.
    PubMed         Abstract available

    Discov Oncol

  9. ZONG S, Gao J
    Identifying the tumor immune microenvironment-associated prognostic genes for prostate cancer.
    Discov Oncol. 2024;15:42.
    PubMed         Abstract available


  10. BAE SY, Kamalanathan K, Galeano-Garces C, Konety BR, et al
    Dissemination of circulating tumor cells in breast and prostate cancer: Implications for early detection.
    Endocrinology. 2024 Feb 15:bqae022. doi: 10.1210.
    PubMed         Abstract available

    Eur J Radiol

  11. GIGANTI F, Asbach P
    The backbone of prostate MRI: Technical acquisition and image quality.
    Eur J Radiol. 2024;172:111320.

    Eur Urol

  12. POPE B, Park G, Lau E, Belic J, et al
    Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
    Eur Urol. 2024 Feb 19:S0302-2838(24)00003-4. doi: 10.1016/j.eururo.2024.

  13. FENG D, Wang J, Wu R, Li D, et al
    Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen Deprivation Therapy Against Prostate Cancer.
    Eur Urol. 2024 Feb 17:S0302-2838(24)00069-1. doi: 10.1016/j.eururo.2024.

  14. DE VOS II, Remmers S, Roobol MJ
    Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinui
    Eur Urol. 2024 Feb 17:S0302-2838(24)00057-5. doi: 10.1016/j.eururo.2024.

    Hum Pathol

  15. MAHLOW J, Barry M, Albertson DJ, Jo YJ, et al
    Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
    Hum Pathol. 2024;144:28-33.
    PubMed         Abstract available

    J Natl Cancer Inst

  16. BASU A, Rais-Bahrami S
    Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
    J Natl Cancer Inst. 2024 Feb 16:djae025. doi: 10.1093.


  17. YE PC, Leu WJ, Yeh TY, Hsu YT, et al
    A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
    Prostate. 2024 Feb 20. doi: 10.1002/pros.24678.
    PubMed         Abstract available

  18. WHITE JA, Kaninjing ET, Adeniji KA, Jibrin P, et al
    Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
    Prostate. 2024 Jan 8. doi: 10.1002/pros.24662.
    PubMed         Abstract available

    Radiologia (Engl Ed)

  19. ALONSO-GONZALEZ R, Abadal Villayandre JM, Galvez Gonzalez E, Alvarez Perez MJ, et al
    Irreversible electroporation: Beyond the limits of tumor ablation.
    Radiologia (Engl Ed). 2024;66:47-56.
    PubMed         Abstract available


  20. PASSARELLI R, Srivastava A
    Editorial Comment: Prostate Cancer Detection Rate of Transperineal Prostate Biopsy: Cognitive Versus Software Fusion, A Multicenter Analysis.
    Urology. 2024 Feb 20:S0090-4295(24)00091-8. doi: 10.1016/j.urology.2024.

  21. HUNG M, Ross A, Li EV, Pavlovich CP, et al
    Prostate Cancer Detection Rate of Transperineal Prostate Biopsy: Cognitive Versus Software Fusion, A Multicenter Analysis.
    Urology. 2024 Feb 20:S0090-4295(24)00093-1. doi: 10.1016/j.urology.2023.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.